Petrichor Healthcare Capital Management

Geneoscopy develops non-invasive diagnostics using stool-derived eukaryotic RNA to prevent, detect, and guide treatment for gastrointestinal diseases. Its platform technology enables early-stage detection of colorectal cancer neoplasms and improves screening compliance.

Palvella Therapeutics is a biopharmaceutical company founded in 2015 and headquartered in Wayne, Pennsylvania. The company focuses on developing pathogenetically targeted therapies for serious and rare genetic skin diseases that lack approved treatments. Its lead candidate, QTORIN 3.9 % rapamycin anhydrous gel, is built on a patented QTORIN platform and is in late‑stage clinical development for two rare genodermatoses. Palvella’s approach emphasizes addressing the root cause of disease and delivering stable, room‑temperature formulations that penetrate the epidermis and dermis.

Evergreen Theragnostics is a radiopharmaceutical contract development and manufacturing organization that provides end-to-end services for radiopharmaceuticals, including manufacturing, technology transfer and method valuation, regulatory support, logistics and distribution, and commercialization. Founded in 2019 and based in Jersey City, New Jersey, the company focuses on theragnostic radiopharmaceuticals in the United States. It emphasizes a skilled team with experience in commercialization, process advancement, and regulatory affairs, serving as a partner for radiopharmaceutical development, manufacturing, and commercialization needs from early-stage development through full-market launch. Its platform supports therapeutic and centrally distributed diagnostic radiopharmaceuticals, enabling organizations to pursue development, manufacturing, and commercialization efficiently.

Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapeutics for immune dysregulation disorders. Its lead asset, AVTX-009, is an anti-IL-1β monoclonal antibody targeting inflammatory diseases.

Fennec Pharmaceuticals Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, that focuses on developing treatments for cancer-related conditions, particularly in pediatric patients. The company’s lead product, PEDMARK, is a novel formulation of Sodium Thiosulfate designed to prevent cisplatin-induced ototoxicity, a common and serious side effect of certain chemotherapy treatments that can lead to permanent hearing loss in children. Fennec Pharmaceuticals is currently advancing PEDMARK through clinical trials, having completed Phase III studies to assess its efficacy and safety. Founded in 1996 and formerly known as Adherex Technologies Inc., the company aims to improve the quality of life for children undergoing chemotherapy by mitigating the risk of hearing loss.

Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.

VERO Biotech LLC is a biopharmaceutical company focused on developing and commercializing innovative products for patients with pulmonary and cardiac conditions. The company specializes in inhaled nitric oxide (NO) delivery systems, which are designed for both hospital settings and longer-term home use. Utilizing its proprietary GeNOsyl drug delivery technology, VERO Biotech offers a user-friendly solution that includes a single-use drug cassette coupled with a portable console or wearable controller. This technology aims to provide a safe and consistent administration of nitric oxide for various therapeutic applications, addressing unmet medical needs such as pulmonary arterial hypertension and hypoxic respiratory failure in newborns. Founded in 2006 and based in Atlanta, Georgia, VERO Biotech was previously known as GeNO LLC.

Palvella Therapeutics is a biopharmaceutical company founded in 2015 and headquartered in Wayne, Pennsylvania. The company focuses on developing pathogenetically targeted therapies for serious and rare genetic skin diseases that lack approved treatments. Its lead candidate, QTORIN 3.9 % rapamycin anhydrous gel, is built on a patented QTORIN platform and is in late‑stage clinical development for two rare genodermatoses. Palvella’s approach emphasizes addressing the root cause of disease and delivering stable, room‑temperature formulations that penetrate the epidermis and dermis.

Fennec Pharmaceuticals Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, that focuses on developing treatments for cancer-related conditions, particularly in pediatric patients. The company’s lead product, PEDMARK, is a novel formulation of Sodium Thiosulfate designed to prevent cisplatin-induced ototoxicity, a common and serious side effect of certain chemotherapy treatments that can lead to permanent hearing loss in children. Fennec Pharmaceuticals is currently advancing PEDMARK through clinical trials, having completed Phase III studies to assess its efficacy and safety. Founded in 1996 and formerly known as Adherex Technologies Inc., the company aims to improve the quality of life for children undergoing chemotherapy by mitigating the risk of hearing loss.

Fennec Pharmaceuticals Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, that focuses on developing treatments for cancer-related conditions, particularly in pediatric patients. The company’s lead product, PEDMARK, is a novel formulation of Sodium Thiosulfate designed to prevent cisplatin-induced ototoxicity, a common and serious side effect of certain chemotherapy treatments that can lead to permanent hearing loss in children. Fennec Pharmaceuticals is currently advancing PEDMARK through clinical trials, having completed Phase III studies to assess its efficacy and safety. Founded in 1996 and formerly known as Adherex Technologies Inc., the company aims to improve the quality of life for children undergoing chemotherapy by mitigating the risk of hearing loss.

Fennec Pharmaceuticals Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, that focuses on developing treatments for cancer-related conditions, particularly in pediatric patients. The company’s lead product, PEDMARK, is a novel formulation of Sodium Thiosulfate designed to prevent cisplatin-induced ototoxicity, a common and serious side effect of certain chemotherapy treatments that can lead to permanent hearing loss in children. Fennec Pharmaceuticals is currently advancing PEDMARK through clinical trials, having completed Phase III studies to assess its efficacy and safety. Founded in 1996 and formerly known as Adherex Technologies Inc., the company aims to improve the quality of life for children undergoing chemotherapy by mitigating the risk of hearing loss.

Tourmaline Bio is a clinical biotechnology company focused on developing transformative medicines aimed at improving the lives of patients suffering from immune diseases. The company is in the late stages of clinical development and is centered on its lead product candidate, TOUR006, a fully human monoclonal antibody designed to selectively target interleukin-6 (IL-6), a significant proinflammatory cytokine implicated in various autoimmune and inflammatory disorders. The IL-6 antibody class has a well-established history, with over two decades of clinical and commercial experience, having successfully treated more than a million patients with diverse autoimmune and inflammatory conditions. Through its innovative research, Tourmaline Bio seeks to address the unmet medical needs of patients affected by life-altering immune diseases.

Aurion Biotechnologies is a clinical-stage biotech company focused on developing advanced therapies for ocular diseases, particularly those leading to blindness. Based in Seattle, Boston, and Tokyo, the company aims to transform the lives of millions by restoring vision through innovative cell therapies. Its lead candidate targets corneal edema and is one of the first clinically validated cell therapies in corneal care. The process involves culturing healthy cells from a donor cornea using a proprietary method, allowing cells from a single donor to potentially treat over 100 recipient eyes. Clinical trials in Japan have shown that patients experience significant and lasting improvements in corneal health indicators, including visual acuity and corneal thickness.

Leukocare is a biotechnology company focused on biopharmaceutical formulation development at the interface of drug substance and drug product. It integrates formulation science with bioinformatics and artificial intelligence to optimize biopharmaceuticals, viral vectors, vaccines, and related products, supporting development from concept to product readiness. The company offers formulation technologies and development services intended to improve stability, safety, and efficacy, with applications including reducing leukocyte activity in extracorporeal blood circuits used in cardiac surgery.

Leukocare is a biotechnology company focused on biopharmaceutical formulation development at the interface of drug substance and drug product. It integrates formulation science with bioinformatics and artificial intelligence to optimize biopharmaceuticals, viral vectors, vaccines, and related products, supporting development from concept to product readiness. The company offers formulation technologies and development services intended to improve stability, safety, and efficacy, with applications including reducing leukocyte activity in extracorporeal blood circuits used in cardiac surgery.

ITM Isotopen Technologien München AG is a biotechnology and radiopharmaceutical company based in Garching, Germany, focusing on the development, manufacturing, and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for cancer treatment. Established in 2004, ITM has built a robust global supply network and accomplished GMP manufacturing capabilities. The company offers a range of products, including EndolucinBeta, a radiopharmaceutical precursor for targeted radionuclide therapy, as well as radionuclides like 225Ac and 213Bi. Additionally, ITM develops automated systems for synthesizing radiolabeled biomolecules and provides GMP radiolabeling services. With a growing portfolio of innovative treatments and partnerships, ITM aims to enhance patient outcomes and quality of life in oncology, specifically addressing conditions such as neuroendocrine cancers and bone metastases while minimizing side effects.

ClearPoint Neuro is a medical device company specializing in platforms for minimally invasive surgical procedures in the brain and heart under direct magnetic resonance imaging (MRI) guidance. Its flagship product, the ClearPoint system, enables precise insertion of catheters, electrodes, and laser fibers for treating neurological conditions and performing biopsies.

ClearPoint Neuro is a medical device company specializing in platforms for minimally invasive surgical procedures in the brain and heart under direct magnetic resonance imaging (MRI) guidance. Its flagship product, the ClearPoint system, enables precise insertion of catheters, electrodes, and laser fibers for treating neurological conditions and performing biopsies.

Founded in 2005, Persivia is a healthcare IT company specializing in population health management. It offers an AI-driven SaaS platform that integrates clinical, socioeconomic, and claims data to provide comprehensive patient insights. The platform supports value-based care programs, quality reporting, care coordination, chronic care management, and clinical analytics for hospitals, payers, providers, ACOs, and PCMH.

CorneaGen is a mission-driven company focused on innovating cornea care to eliminate corneal blindness globally. It develops advanced medical devices, biologics, and therapeutics aimed at improving the treatment and care provided by corneal surgeons. CorneaGen offers a comprehensive range of services, including the delivery of high-quality tissue, surgeon education, and advocacy for patient access and reimbursement policies. By equipping eye surgeons with innovative tools and resources, CorneaGen strives to restore sight for individuals suffering from corneal conditions, thereby transforming the landscape of corneal surgery and enhancing patient outcomes.

CorneaGen is a mission-driven company focused on innovating cornea care to eliminate corneal blindness globally. It develops advanced medical devices, biologics, and therapeutics aimed at improving the treatment and care provided by corneal surgeons. CorneaGen offers a comprehensive range of services, including the delivery of high-quality tissue, surgeon education, and advocacy for patient access and reimbursement policies. By equipping eye surgeons with innovative tools and resources, CorneaGen strives to restore sight for individuals suffering from corneal conditions, thereby transforming the landscape of corneal surgery and enhancing patient outcomes.